Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
August 2017
-
Media ReleaseNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular riskStudy showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in…
-
Media ReleaseNovartis appoints Bertrand Bodson as Chief Digital OfficerNew leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury'…
-
Media ReleaseNovartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitorApproval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole…
-
Media ReleaseNovartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistantCe candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la…
-
Media ReleaseNovartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malariaCompound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first…
-
Media ReleaseNovartis und Medicines for Malaria Venture starten in Afrika eine Patientenstudie mit KAF156, einem neuartigen Wirkstoff gegen multiresistente MalariaDer Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
July 2017
-
Media ReleaseSandoz expands partnership with World Child Cancer, to help children access treatment in four developing countriesExpanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is…
-
Media ReleaseNovartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first…
-
Media ReleaseDie Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer ProdukteDer Nettoumsatz liegt auf Vorjahresniveau (0% kWk[1], -2% USD), wobei die Wachstumstreiber die Einbussen durch Generika von Glivec/Gleevec wettmachen: Cosentyx (USD 490 Millionen, +90% kWk)…
-
Media ReleaseLes résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateursChiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx (…
-
Media ReleaseQ2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative productsNet sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications…
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be…
Pagination
- ‹ Previous page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- …
- 100
- › Next page